Spectre Biotech

Spectre Biotech operates at the intersection of digital health, neurotechnology, healthcare, and software, offering cloud-based tools for EEG data processing and interpretation. Its stated audience includes healthcare professionals and researchers, while its described customer settings also extend to universities, research labs, esports, and motorsport organizations. The product range suggests an effort to serve both individual professionals and larger organizations: Basic Plan covers dEEG and qEEG reporting, Pro Plan adds biomarkers and neurofeedback-related workflows, and Structure Plan offers organization-scale workspaces and research publications. Those features provide a specific point of distinction in the available profile: the offering combines EEG reporting with rehabilitation, training, and neurofeedback capabilities rather than being described only as an imaging-processing tool. Its competitive position should therefore be treated as a focused specialist offering in EEG analysis software, not as a proven market leader. The company’s differentiation is clearest in the breadth of its workflow features and customer settings.

Spectre Biotech was founded in 2020 and is listed as active, with an employee-size band of 1–10. This tiering indicates an offering designed for more than one type of user, but it does not by itself establish customer growth or commercial traction. With no longitudinal employee figures or product-adoption measures, the company’s growth trajectory cannot be quantified.